



Summary of Studies Supporting USDA Product Licensure

Establishment Name	Elanco US Inc.
USDA Vet Biologics Establishment Number	196
Product Code	1559.23
True Name	Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia-Chlamydia Psittaci Vaccine, Killed Virus, Killed Chlamydia
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	
Date of Compilation Summary	October 26, 2017

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy
Pertaining to	Feline Calicivirus
Study Purpose	To demonstrate effectiveness against respiratory disease due to feline calicivirus
Product Administration	
Study Animals	
Challenge Description	
Interval observed after challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance. Study data, however, are no longer available.
USDA Approval Date	April 13, 1990

Study Type	Efficacy
Pertaining to	Feline Calicivirus (FCV)
Study Purpose	To demonstrate effectiveness against hypervirulent systemic (hemorrhagic) form of feline calicivirus disease
Product Administration	Two doses administered subcutaneously three weeks apart.
Study Animals	29 cats, 8 weeks old, randomly divided into 20 vaccinates and 9 non-vaccinated controls.
Challenge Description	Virulent FCV was administered 14 days after second vaccination
Interval observed after challenge	Cats were observed for clinical signs for 14 days post challenge
Results	<p>The primary outcome was the presence or absence of hemorrhagic calicivirus disease. An animal was considered affected if any clinical signs of FCV infection were present.</p> <p>Positive for clinical FCV: Vaccinates: (0/20) (0%) positive Controls: 9/9 (100%) positive</p> <p>Raw Data for each day postchallenge (DPC): Data table is appended to the end of the summary.</p>
USDA Approval Date	February 2, 2005

Clinical Observations for FCV Challenge

CatID	Vaccinates																			
	00PC	10PC	20PC	30PC	40PC	50PC	60PC	70PC	8PC	90PC	100PC	110PC	120PC	130PC	140PC					
1																				
2					Dep. Deh															
3																				
4																				
5																				
6																				
7																				
8			Deh																	
9																				
10																				
11			Deh																	
12																				
13											P									
14			Deh								Es									
15																				
16																				
17																				
18			Deh																	
19																				
20																				
Es - Edema slight																				
Deh - Dehydration																				
Dep - Depression/Lethargy																				

Blanks=no signs observed

Clinical Observations for FCV Challenge

Placebo Controls																	
Case ID	0DPC	1DPC	2DPC	3DPC	4DPC	5DPC	6DPC	7DPC	8PC	9DPC	10DPC	11DPC	12DPC	13DPC	14DPC		
1					Deh	Dep, Es	Es	Es	Py, Ea	Deh, Py, Em, Al, Other ⁴	Deh, Py, Es, Al, Other ⁴	SS, NB, Py, Es	SS, NB, Deh, Py	SS, NB, Deh, Py	SS, NB, Deh, Py		
2					Dep, Deh, Os, Other ¹	Dep, Em, Os, Rs	Deh, An, Em, Ee (ears)	Deh, An, Em (muzzle), Ee (Ears), Rm	Deh, An, Py, Ee	Dep, Deh, An, Py, Em (muzzle), Ee (ears), Om, Rm	Mb, Dep, Deh, An, Py, Em (muzzle), Ee (Ears), Om, Rm	SI, Deh, Py, Ee, Om, Rm	SI, Deh, Py, Ee, Om	SI, Mb, Deh, Py, Ee, Rm	SI, Mb, Deh, Py, Ee, Rm	SI, Mb, Deh, Py, Ee	
3				Dep, Deh, An, Al, L	Deh, An, Es	Deh, Em	Deh, An, Py, L, Em (Ears and paws), Ee (face)	Deh, An, Py, Ee, Rm	Dep, Deh, An, Py, Ee (hind feet), Ee (muzzle & Ears)	Dep, Deh, An, Py, Ee, Rm	NB, Mb, Deh, An, Py, Ee, Al, Other ⁴	SS, Deh, Py, Em, Ee, Other ⁴	SS, B, Py, Em (Ears), Ee (Muzzle, hind paws), other ⁵	SS, B, Deh, Py, Em (ears), Ee (muzzle, hind paws)	SS, NB, Deh, Py, ee	SS, NB, Deh, Py, ee	
4			Deh	Deh	Deh	Deh	Deh, Es	Es	Es, Other ³	MS, NB, Es, OM	SS, NB, Deh, Py, Es						
5					Deh	Deh	Deh, An, Em	Deh, An, Es	Deh, An, Es	Py, Es, Al	SS, Py, Es, Al	B	B	NB, Py	NB, Py	NB, Py	
6					Dep, Deh	Dep, Es	Es	Es	Es		NB	NB	NB	NB	NB	NB	
7				NB	Deh	Deh, Em, L, Sn, Other ²	Deh, An, L, Es (Ears), Ee (muzzle)	Dep, Deh, An, Ee, Rm	Dep, Deh, An, Ee, Rm	Dead	Dead	Dead	Dead	Dead	Dead	Dead	
8				Deh	Dep, Deh	Dep, Deh	Dep, An, Es, slight hair loss on ears	Deh, An, Es, some hair loss on ears	Deh, Ea	Deh, An, Es	Deh, An, Es	NB	NB				
9						Deh, Es	Deh, Es (muzzle), OS or Om	Es	Om								
							MS - Oral Ulcer Multiple Small (<4mm)	Mb - Dyspnea Mouth Breathing	Deh - Dehydration	Other -							
							ML - Oral Ulcer Multiple Large (>4mm)	OS - Ocular Discharge Serous	Dep - Depression/Letharg	1-Left ear skin inflammation							
							NB - External Ulcer Non-Bleeding	OM - Ocular Discharge Mucopurulent	L - Limping	2 - lungs have fluid							
							B - External Ulcer Bleeding	RS - Nasal Discharge Serous	Sn - Sneezing	3 - Ears hot and red							
							Py - Pyoderma	RM - Nasal Discharge Mucopurulent	Al - Alopecia	4 - shaking							
									An - Anorexia	5 - tip of tail gone							

Blanks=no signs observed

Study Type	Efficacy
Pertaining to	Feline Chlamydia Psittaci (FCP)
Study Purpose	To demonstrate effectiveness against FCP
Product Administration	Two doses administered 21 days apart subcutaneously (SC) or Intramuscular (IM).
Study Animals	Thirty (30) cats, 16 to 20 weeks of age. Cats were allocated into one vaccinated group of 20 cats, 10 SC and 10 IM, and one group of 10 non-vaccinated controls.
Challenge Description	21 days post second vaccination all cats were challenged with FCP.
Interval observed after challenge	Rectal temperatures and clinical signs were observed daily for 28 days post challenge.
Results	<p>Vaccinates and controls were evaluated per the criteria in 9 CFR 113.71.(3)</p> <p>A significant difference in clinical signs was observed between vaccinates and controls using a scoring sytem approved by APHIS.</p> <p>Requirements of 9 CFR 113.71 (3) were met.</p> <p>Raw Data: Data tables are appended to the end of the summary.</p>
USDA Approval Date	April 13, 1990

Daily Rectal Temperatures Following FCP Challenge

Vaccinates

Cat ID	Route	1DPC	2DPC	3DPC	4DPC	5DPC	6DPC	7DPC	8DPC	9DPC	10DPC	11DPC	12DPC	13DPC	14DPC	15DPC	16DPC	17DPC	18DPC	19DPC	20DPC	21DPC	22DPC	23DPC	24DPC	25DPC	26DPC	27DPC	28DPC		
1	M	101.8	102.2	102.8	103.8	102.6	102.4	101.6	102.6	102.4	102.8	102.0	102.6	102.0	102.0	102.4	102.8	102.4	101.6	102.6	101.6	102.6	102.0	101.8	101.6	101.4	101.8	102.2	103.2		
2	M	101.9	104.0	101.9	102.6	101.4	102.2	101.6	102.0	101.4	102.2	101.8	101.9	102.6	102.0	102.4	102.4	102.2	101.6	101.7	101.8	102.2	101.4	101.6	101.6	101.7	101.4	101.8	102.0		
3	M	101.4	102.4	102.5	102.6	102.0	101.8	102.0	102.0	102.3	102.4	102.2	102.0	102.4	101.6	102.4	102.6	102.8	102.0	102.0	102.5	102.7	102.6	102.0	102.4	101.8	101.6	102.2	102.4	103.0	
4	M	101.4	102.6	103.2	103.4	102.6	102.4	102.2	102.4	102.6	102.6	102.6	103.0	102.2	101.8	102.2	102.4	102.4	102.2	102.4	102.4	102.2	102.0	101.8	102.4	102.0	102.2	102.0	102.6	103.0	
5	M	101.4	103.0	102.3	102.0	101.6	102.6	102.0	102.4	102.0	102.8	102.0	102.6	102.0	102.6	102.6	104.0	102.4	102.2	102.4	102.2	102.2	102.2	101.4	102.0	101.8	102.2	102.2	103.0	102.2	
6	M	101.8	103.2	102.4	103.6	102.6	102.0	101.6	101.6	102.5	102.6	102.0	103.4	102.2	102.0	101.6	104.0	103.4	101.4	102.2	102.2	102.2	101.6	101.8	102.0	102.4	102.0	102.4	102.4	102.0	
7	M	101.8	103.0	103.2	103.6	102.6	102.8	102.4	102.6	101.6	102.4	102.0	102.4	103.0	102.4	102.6	102.6	102.2	101.8	102.2	102.2	102.6	102.6	102.0	102.2	102.2	102.8	102.5	102.6	102.6	
8	M	101.4	101.6	103.2	102.6	101.8	101.6	101.6	101.6	101.4	102.0	101.8	102.0	101.6	102.2	101.6	101.6	101.8	101.4	101.7	101.8	102.0	101.0	102.0	101.2	101.8	101.6	102.4	103.0	103.0	
9	M	102.0	104.0	103.5	103.6	103.0	102.8	102.6	102.0	102.6	102.8	101.8	102.2	102.2	102.2	102.6	102.6	103.0	101.8	103.2	102.8	102.4	102.3	102.0	102.0	102.8	102.6	103.0	103.2	103.2	
10	M	101.8	102.8	102.7	103.8	102.7	102.6	102.2	101.4	102.4	102.6	102.0	103.3	NA	NA	102.8	102.6	102.0	102.0	103.8	102.6	103.0	102.1	102.2	102.0	102.4	102.8	102.7	102.8	102.8	
11	SC	101.4	104.0	101.8	103.0	102.2	101.8	101.8	101.6	102.0	102.6	103.0	103.2	103.0	NA	103.2	102.4	102.8	102.0	103.4	102.2	103.0	102.6	102.2	102.0	103.0	103.8	104.2	103.4	103.4	
12	SC	102.2	102.8	103.0	103.0	103.0	101.4	101.8	102.8	101.6	102.8	102.4	101.6	101.8	102.2	102.0	104.4	102.2	101.8	102.2	102.6	102.2	101.0	101.8	101.7	102.0	102.2	102.5	103.2	103.2	
13	SC	101.8	103.0	103.4	103.6	103.0	102.6	103.2	102.4	102.4	102.6	102.6	102.0	102.4	101.8	102.4	102.8	102.8	102.4	103.2	102.8	102.2	102.4	102.8	102.0	102.0	102.4	102.8	102.4	102.4	
14	SC	102.2	102.8	103.0	102.6	101.4	102.4	102.2	101.8	101.6	102.2	101.8	101.7	101.8	101.6	101.4	102.6	102.2	102.6	102.6	102.6	102.5	102.8	103.4	104.0	103.4	102.8	103.6	103.8	103.2	
15	SC	102.4	103.2	102.8	102.4	101.4	102.0	101.4	102.2	102.3	103.0	101.8	102.4	104.0	101.6	101.8	102.2	103.0	102.2	102.4	102.2	102.4	101.4	102.2	101.6	102.0	102.2	102.0	101.8	102.2	
16	SC	102.2	102.5	102.6	102.6	101.8	102.2	102.0	101.6	102.2	102.4	102.8	102.2	102.0	102.0	102.0	104.2	104.2	102.4	102.2	102.0	102.0	102.8	101.4	101.8	102.0	103.4	102.0	102.0	102.6	102.6
17	SC	102.6	102.4	103.1	103.2	102.5	102.4	102.8	102.8	102.1	102.2	102.4	101.6	103.0	102.4	103.4	102.6	102.8	101.4	103.2	102.8	102.0	101.8	102.4	102.4	102.4	102.4	102.8	103.0	103.8	103.8
18	SC	101.6	101.6	102.5	103.8	101.8	102.6	102.6	101.4	101.6	102.2	102.0	102.4	101.8	102.2	102.6	103.4	103.2	102.4	102.1	102.0	102.0	102.2	101.8	102.0	101.8	102.0	101.6	101.8	102.6	102.6
19	SC	102.6	103.9	103.1	103.0	102.4	102.4	102.6	101.8	102.2	103.0	102.0	101.8	103.2	103.0	102.2	102.6	102.2	101.4	102.4	101.6	102.2	101.6	102.0	101.8	102.6	103.0	102.4	102.2	102.2	102.2
20	SC	101.8	102.2	102.2	103.0	101.6	102.0	101.4	101.1	101.6	102.4	102.0	102.3	101.4	102.2	102.0	101.4	101.8	101.4	102.0	101.6	101.6	101.8	102.2	102.2	102.6	102.2	102.0	102.6	102.6	102.6

No Vaccinated Controls

Cat ID	Route	1DPC	2DPC	3DPC	4DPC	5DPC	6DPC	7DPC	8DPC	9DPC	10DPC	11DPC	12DPC	13DPC	14DPC	15DPC	16DPC	17DPC	18DPC	19DPC	20DPC	21DPC	22DPC	23DPC	24DPC	25DPC	26DPC	27DPC	28DPC		
1		101.8	102.4	102.5	102.4	102.4	102.8	102.0	102.0	102.6	103.0	102.8	103.6	104.0	103.8	104.2	105.2	104.2	104.8	105.5	104.8	103.8	102.4	103.8	103.6	103.6	102.8	103.2	103.6	103.6	
2		103.0	102.8	102.7	102.0	101.8	102.4	102.4	102.6	102.3	102.8	102.8	103.3	102.8	102.6	103.2	104.4	102.4	105.2	105.2	105.0	103.8	104.4	104.0	104.1	103.8	103.4	103.3	103.6	103.6	
3		102.4	103.2	103.5	103.6	103.0	102.2	102.8	102.4	101.7	102.6	102.6	103.4	103.4	102.8	104.4	103.8	104.8	104.8	104.6	103.8	102.6	102.1	103.4	103.0	103.6	103.2	104.0	103.0	103.0	
4		101.4	102.8	102.8	103.0	101.6	102.2	101.4	101.8	102.2	102.0	102.8	103.6	102.4	101.8	102.2	103.2	103.6	102.6	103.1	103.2	104.0	103.4	103.4	103.8	104.6	103.4	104.3	103.0	103.0	
5		101.5	102.6	102.1	102.4	102.0	101.6	101.8	101.4	101.4	102.0	102.0	102.5	103.8	105.4	104.2	104.2	103.4	103.6	103.4	103.4	102.2	103.2	103.4	103.1	103.2	103.0	102.6	103.4	103.4	
6		103.0	102.4	103.5	102.4	102.4	103.0	102.4	101.8	102.4	103.2	101.8	101.7	103.0	102.8	102.6	102.8	102.2	103.0	104.2	103.2	102.6	102.4	102.4	102.8	103.2	103.0	103.3	103.0	103.0	
7		102.4	102.6	103.1	103.6	103.0	102.2	101.8	102.2	101.6	102.6	102.0	101.8	102.8	102.6	102.6	103.8	103.2	103.8	104.4	104.6	101.4	103.3	102.8	102.8	103.2	102.8	102.5	102.0	102.0	
8		101.4	103.0	103.0	103.4	103.2	102.0	101.8	102.4	102.2	102.2	102.4	102.8	101.8	103.8	104.0	104.4	104.4	104.6	104.2	104.0	103.8	102.8	103.0	103.6	104.6	103.4	103.3	103.0	103.0	
9		102.2	103.0	102.1	103.0	103.0	102.2	101.6	102.0	101.6	102.4	102.6	102.4	102.6	102.0	102.2	103.8	105.8	104.6	105.0	103.8	104.0	104.4	104.0	102.6	104.6	103.4	102.3	102.2	102.2	
10		101.4	104.0	104.2	104.4	103.6	103.8	103.4	101.4	103.8	103.2	102.2	102.4	104.2	103.4	105.0	104.2	102.8	104.4	104.0	104.5	104.8	101.6	104.0	104.0	104.0	103.4	103.8	103.8	103.0	103.0

Study Type	Efficacy
Pertaining to	Feline Leukemia Virus (FeLV)
Study Purpose	To demonstrate effectiveness against FeLV
Product Administration	Two doses administered 21 days apart subcutaneously (SC) or Intramuscular (IM).
Study Animals	Forty (40) cats 16 to 20 weeks of age. Cats were allocated into one vaccinated group of 20 cats, 10 SC and 10 IM, and one group of 20 non-vaccinated controls.
Challenge Description	14 days post second vaccination all cats were challenged with virulent FeLV.
Interval observed after challenge	All cats were bled once a week for 10 weeks post challenge.
Results	<p>Serum each week was tested for the presence of FeLV (viremia). Animals were considered affected by the challenge if they established a persistent viremia (i.e., tested positive and remained positive).</p> <p>Raw Data: Data tables are appended to the end of the summary.</p>
USDA Approval Date	April 13, 1990

Development of FeLV Viremia in Cats

FeLV Vaccinates

Cat ID	Vaccination Route	ODP C	7DP C	14DP C	21DP C	28DP C	35DPC	45DP C	50DPC	56DPC	63DP C	70DP C
1	IM	-	-	-	-	-	-	-	-	-	-	-
2	IM	-	-	+	+	+	+	+	+	+	+	+
3	IM	-	-	+	-	-	-	-	-	-	-	-
4	IM	-	-	-	-	NA*	NA	NA	NA	NA	NA	NA
5	IM	-	-	+	+	+	+	+	+	+	+	+
6	IM	-	-	-	-	-	-	-	-	-	-	-
7	IM	-	-	-	+	+	+	+	-	-	-	-
8	IM	-	-	+	+	+	+	+	+	+	+	+
9	IM	-	-	-	-	-	-	-	-	-	-	-
10	IM	-	-	+	+	+	-	-	-	-	-	-
11	SC	-	-	-	-	-	-	-	-	-	-	-
12	SC	-	-	+	+	+	+	+	+	+	+	+
13	SC	-	-	-	-	-	-	-	-	-	-	-
14	SC	-	-	-	-	-	-	-	-	-	-	-
15	SC	-	-	+	+	+	+	+	+	+	+	+
16	SC	-	-	-	-	-	-	-	-	-	-	-
17	SC	-	-	-	-	-	-	-	-	-	-	-
18	SC	-	-	-	-	-	-	-	-	-	-	-
19	SC	-	-	-	-	-	-	-	-	-	-	-
20	SC	-	-	-	+	+	+	+	+	+	+	+

Non-Vaccinated Controls

Cat ID	Vaccination Route	ODP C	7DP C	14DP C	21DP C	28DP C	35DPC	45DP C	50DPC	56DPC	63DP C	70DP C
21	NA	-	-	-	+	+	+	+	+	+	+	+
22	NA	-	-	+	+	+	+	+	+	+	+	+
23	NA	-	-	-	+	+	+	+	+	+	+	+
24	NA	-	-	+	+	+	+	+	+	+	+	+
25	NA	-	-	+	+	+	+	+	+	+	+	+
26	NA	-	-	+	+	+	+	+	+	+	+	+
27	NA	-	-	-	-	+	+	-	-	-	-	-
28	NA	-	-	-	+	+	+	+	+	+	+	+
29	NA	-	-	+	+	+	+	+	+	+	+	+
30	NA	-	-	+	+	+	+	+	+	+	+	+
31	NA	-	-	+	+	+	+	+	+	+	+	+
32	NA	-	-	-	-	-	-	-	-	-	-	-
33	NA	-	-	-	-	-	-	-	-	-	-	-
34	NA	-	-	-	+	+	-	-	-	-	-	-
35	NA	-	-	+	+	+	+	+	+	+	+	+
36	NA	-	-	-	+	+	+	+	+	+	+	+
37	NA	-	-	-	+	+	+	+	+	+	+	+
38	NA	-	-	-	+	+	+	+	+	+	+	+
39	NA	-	-	+	+	+	+	+	+	+	+	+
40	NA	-	-	-	+	+	+	+	+	+	+	+

* - Cat found dead (causes not due to FeLV) after sampling on 21DPC

DPC = Days post challenge

NA = Not Applicable

Study Type	Efficacy
Pertaining to	Feline Rhinotracheitis (FVR)
Study Purpose	To demonstrate effectiveness against FVR
Product Administration	
Study Animals	
Challenge Description	
Interval observed after challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance. Study data, however, are no longer available.
USDA Approval Date	April 13, 1990

Study Type	Efficacy
Pertaining to	Feline Panleukopenia Virus (FPV)
Study Purpose	To demonstrate effectiveness against FPV
Product Administration	
Study Animals	
Challenge Description	
Interval observed after challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance. Study data, however, are no longer available.
USDA Approval Date	April 13, 1990

Study Type	Safety																																																																					
Pertaining to	All																																																																					
Study Purpose	Demonstrate safety of product under typical use conditions																																																																					
Product Administration	Two doses were administered subcutaneously (SC) at 3- to 4-week intervals in cats 8 weeks of age or older.																																																																					
Study Animals	A total of 720 privately owned cats.																																																																					
Challenge Description	NA																																																																					
Interval observed after challenge	Felines were observed for 30 minutes following the first vaccination and daily till the second vaccination. Each animal was then observed for 30 minutes following the second vaccination and again daily for 21 days.																																																																					
Results	<p>Frequency of Adverse Events:</p> <table border="1"> <thead> <tr> <th colspan="7">Post Vaccination Reaction Occurrence by doses. Total Doses = 1416</th> </tr> <tr> <th rowspan="2">Reaction Category</th> <th colspan="2">≤ 10 Week old cats</th> <th colspan="2">≥ 11 Weeks old cats</th> <th colspan="2">Total Doses</th> </tr> <tr> <th>#</th> <th>Percent</th> <th>#</th> <th>Percent</th> <th>#</th> <th>Percent</th> </tr> </thead> <tbody> <tr> <td>No adverse events</td> <td>563</td> <td>96.2%</td> <td>813</td> <td>97.8%</td> <td>1376</td> <td>97.2%</td> </tr> <tr> <td>Fever</td> <td>4</td> <td>0.7%</td> <td>0</td> <td>0%</td> <td>4</td> <td>0.3%</td> </tr> <tr> <td>Lethargy</td> <td>19</td> <td>3.2%</td> <td>16</td> <td>1.9%</td> <td>35</td> <td>2.5%</td> </tr> <tr> <td>Anorexia</td> <td>2</td> <td>0.3%</td> <td>7</td> <td>0.8%</td> <td>9</td> <td>0.6%</td> </tr> <tr> <td>Injection Site Swelling</td> <td>1</td> <td>0.2%</td> <td>1</td> <td>0.1%</td> <td>2</td> <td>0.1%</td> </tr> <tr> <td>Injection Site Pain</td> <td>4</td> <td>0.7%</td> <td>6</td> <td>0.7%</td> <td>10</td> <td>0.7%</td> </tr> <tr> <td>Vocalization</td> <td>1</td> <td>0.2%</td> <td>2</td> <td>0.2%</td> <td>3</td> <td>0.2%</td> </tr> </tbody> </table>	Post Vaccination Reaction Occurrence by doses. Total Doses = 1416							Reaction Category	≤ 10 Week old cats		≥ 11 Weeks old cats		Total Doses		#	Percent	#	Percent	#	Percent	No adverse events	563	96.2%	813	97.8%	1376	97.2%	Fever	4	0.7%	0	0%	4	0.3%	Lethargy	19	3.2%	16	1.9%	35	2.5%	Anorexia	2	0.3%	7	0.8%	9	0.6%	Injection Site Swelling	1	0.2%	1	0.1%	2	0.1%	Injection Site Pain	4	0.7%	6	0.7%	10	0.7%	Vocalization	1	0.2%	2	0.2%	3	0.2%
Post Vaccination Reaction Occurrence by doses. Total Doses = 1416																																																																						
Reaction Category	≤ 10 Week old cats		≥ 11 Weeks old cats		Total Doses																																																																	
	#	Percent	#	Percent	#	Percent																																																																
No adverse events	563	96.2%	813	97.8%	1376	97.2%																																																																
Fever	4	0.7%	0	0%	4	0.3%																																																																
Lethargy	19	3.2%	16	1.9%	35	2.5%																																																																
Anorexia	2	0.3%	7	0.8%	9	0.6%																																																																
Injection Site Swelling	1	0.2%	1	0.1%	2	0.1%																																																																
Injection Site Pain	4	0.7%	6	0.7%	10	0.7%																																																																
Vocalization	1	0.2%	2	0.2%	3	0.2%																																																																
USDA Approval Date	March 24, 2005																																																																					